Patents by Inventor Xiaoheng Zhang

Xiaoheng Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230216487
    Abstract: The present application provides a level shift circuit, an integrated circuit, and an electronic device. The level shift circuit comprises: an input module, configured to output a first control signal according to a first power supply voltage signal, first and second input voltages, inverted voltages of the first and second input voltages that received; a control voltage generation module, configured to receive the first control signal, and generate a plurality of node voltages according to the first control signal and a second power supply voltage signal; and output control modules, configured to generate first to fourth output signals according to the node voltages and the first power supply voltage signal, or generate fifth to eighth output signals according to the second power supply voltage signal and the node voltages.
    Type: Application
    Filed: December 15, 2022
    Publication date: July 6, 2023
    Applicants: Beijing ESWIN Computing Technology Co., Ltd., Hefei ESWIN Computing Technology Co., Ltd.
    Inventors: Xiaoheng Zhang, Jiajhang Wu, Haohao Zhang
  • Patent number: 9771390
    Abstract: The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 26, 2017
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Xiaoheng Zhang, Lijun Mei
  • Patent number: 9617227
    Abstract: A concise, efficient and cost- and time-saving process for the preparation of a quinazoline derivative of formula A given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of Formula B: with 3-chloro-4-fluoroaniline (VI) in the presence of a N,N-dialkyl formamide acetal, a Bronsted acid catalyst, and a solvent in a one-pot reaction.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: April 11, 2017
    Assignee: SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD.
    Inventors: Xiaoheng Zhang, Xizhou Lv
  • Publication number: 20160304551
    Abstract: The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 20, 2016
    Inventors: Xiaoheng Zhang, Lijun Mei
  • Publication number: 20160200688
    Abstract: A concise, efficient and cost- and time-saving process for the preparation of a quinazoline derivative of formula A given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of Formula B: with 3-chloro-4-fluoroaniline (VI) in the presence of a N,N-dialkyl formamide acetal, a Bronsted acid catalyst, and a solvent in a one-pot reaction.
    Type: Application
    Filed: June 10, 2014
    Publication date: July 14, 2016
    Inventors: Xiaoheng Zhang, Xizhou Lv
  • Patent number: 8710221
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: April 29, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Xiaoheng Zhang, YiJing Chen, ChunFang Xu, Yong Mu
  • Patent number: 8648188
    Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 11, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lijun Mei, Yung-Fa Chen
  • Publication number: 20140024829
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 23, 2014
    Applicant: SCINOPHARM TAIWAN, LTD.
    Inventors: Yung-Fa CHEN, Julian Paul HENSCHKE, Xiaoheng ZHANG, YiJing CHEN, ChunFang XU, Yong MU
  • Patent number: 8586729
    Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 19, 2013
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei
  • Patent number: 8563719
    Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: October 22, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Yuanlian Liu, Guodong Chu, Xiaoheng Zhang
  • Publication number: 20130005971
    Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.
    Type: Application
    Filed: March 23, 2011
    Publication date: January 3, 2013
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Yuanlian Liu, Guodong Chu, Xiaoheng Zhang
  • Patent number: 8338586
    Abstract: A method of making cladribine with an increased purity comprising: a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; and c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: December 25, 2012
    Assignee: ScinoPharm (Kunshan) Biochemical Technology Co., Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Chu Guodong, Lijun Mei, Yung Fa Chen
  • Publication number: 20120197010
    Abstract: A method of making cladribine with an increased purity comprising: a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; and c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.
    Type: Application
    Filed: March 26, 2012
    Publication date: August 2, 2012
    Applicant: ScinoPharm (Kunshan) Biochemical Technology Co., Ltd.
    Inventors: Julian Paul HENSCHKE, Xiaoheng Zhang, Guodong Chu, Lijun Mei, Yung Fa Chen
  • Patent number: 8232387
    Abstract: A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated ?-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: July 31, 2012
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Guodong Chu, Lijun Mei, Yung Fa Chen
  • Patent number: 8212021
    Abstract: A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: July 3, 2012
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lunghu Wang, Yung Fa Chen
  • Publication number: 20120010397
    Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 12, 2012
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lijun Mei, Yung-Fa Chen
  • Publication number: 20110046363
    Abstract: A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated ?-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.
    Type: Application
    Filed: August 17, 2010
    Publication date: February 24, 2011
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Guodong Chu, Lijun Mei, Yung Fa Chen
  • Publication number: 20100087637
    Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 8, 2010
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei
  • Publication number: 20100036112
    Abstract: A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.
    Type: Application
    Filed: August 10, 2009
    Publication date: February 11, 2010
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lunghu Wang, Yung Fa Chen